JPRN-jRCTs062220084招募中2 期
Exploratory study to investigate the efficacy and safety of a novel oral mucosa protective material (development code:726X8-2) in patients with cancer chemotherapy-induced oral mucositis
Omori Kazuhiro0 个研究点目标入组 30 人开始时间: 2023年1月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable(—)
- 性别
- All
入选标准
- •Patients who meet all the following criteria will be considered for this study
- •1) Clinically diagnosed oral mucositis (site of onset: lip or tongue) with contact to the cut or sharp edges of the teeth associated with cancer chemotherapy (including molecular targeted drugs)
- •2) Grade rating of oral mucositis and oral pain as per CTCAE v5.0/MedDRA/J v25.1 as Grade 2 or 3
- •3) Patient is receiving concomitant cancer chemotherapy or has completed (or is scheduled to complete) a full course of chemotherapy as of the start of the treatment period (Day 1).
- •However, if the chemotherapy is to be started during the drug withdrawal period between courses, the patient is not eligible for the above. In such cases, the schedule for the start of the treatment period (Day 1) of this study should be adjusted so that the chemotherapy is being administered concurrently. In addition, if there are plans to change the chemotherapy regimen, the change should be implemented prior to this study. In both cases, it is acceptable to confirm that other criteria are met before inclusion
- •4) Age 18 years or older at the time of consent
- •5) ECOG PS is 0 or 1
- •6) Functionally able to take food orally
排除标准
- •Any of the following criteria shall not be included in this study
- •1) Patients undergoing head and neck radiation therapy, performed or scheduled to be performed as prior therapy
- •2) Patients scheduled for or undergoing hematopoietic cell transplantation
- •3) Present number of teeth: less than 10 teeth
- •4) Patients with edentulous jaws
- •5) Allergic to CPC or resin
- •6) Pregnant or possibly pregnant
- •7) Is or will be a user of mucous membrane protectants (Episil Oral Solution), medical narcotics, opioid preparations, steroid ointment for oral use (dexamethasone)
- •8) Has a dental treatment plan
- •9) Patients who are unable or unwilling to perform patient assessments properly under physician supervision
- •10) Other clinical or social factors, conflicts of interest, or other reasons that make the investigator/participating physician inappropriate as a subject for this clinical trial
研究者
相似试验
进行中(未招募)
1 期
Reseach study that will evaluate the efficacy and safety of Bilastine in reducing itching in patients with chronic spontaneous urticaria and other skin diseases.Chronic spontaneous urticaria and the following skin disorders:1 - Eczema/dermatitis (acute eczema, chronic eczema, contact dermatitis, atopic dermatitis, nummular eczema, autosensitisation dermatitis, dyshidrotic eczema, asteatotic eczema, lichen simplex chronicus).2 - Prurigo (acute prurigo, subacute prurigo, chronic prurigo).3 - Cutaneous pruritus (systemic cutaneous pruritus, local cutaneous pruritus).MedDRA version: 19.0Level: HLTClassification code 10012435Term: Dermatitis and eczemaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 19.0Level: PTClassification code 10037083Term: PrurigoSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 19.0Level: PTClassification code 10052568Term: Urticaria chronicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2016-001505-17-ESFAES FARMA, S.A.115
进行中(未招募)
1 期
Reseach study that will evaluate the efficacy and safety of Bilastine in reducing itching in patients with chronic spontaneous urticaria and other skin diseases.EUCTR2016-001505-17-HUFAES FARMA, S.A.115
招募中
1 期
Clinical Trial for Prevention of Cisplatin-Induced Renal NephrotoxicityCancerJPRN-jRCTs041220021Kondo Masashi21
招募中
Unknown
Exploratory study of CLZ-BM3D in patients with peripheral occlusive arterial diseasePatients with peripheral occlusive arterial diseaseJPRN-jRCT2072220114akamura Masato24
进行中(未招募)
1 期
The exploratory study of EFE in COVID-19 patientsCOVID-19JPRN-jRCT2031210063Odaguchi Hiroshi156
